A Study of GC101 TIL in Advanced Melanoma (BZ)

NCT06120712 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor Infiltrating Lymphocytes
Safety
Melanoma
Efficacy
Adverse Drug Event

Interventions

BIOLOGICAL: GC101 TIL

Sponsor

Shanghai Juncell Therapeutics